Andreas Kogelnik
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Andy Kogelnik)
Andreas ("Andy") M. Kogelnik, MD, PhD, is an internal medicine and infectious diseases specialist and the director of the Open Medicine Institute, Mountain View, California, US.[1] His interests are in bioinformatics and genomic medicine and is committed to the study and treatment of ME/CFS and other chronic illnesses.[1]
Education[edit | edit source]
- MD from Emory University[1]
- PhD in bioengineering from Georgia Tech[1]
- Residency in internal medicine at Stanford University[1]
- Fellowship in infectious diseases at Stanford University[1]
ME/CFS Common Data Element (CDE) Project[edit | edit source]
Kogelnik is a member of the Immune Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project, sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[2]
Research publications on ME/CFS[edit | edit source]
- 2006, Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue[3] - (Abstract)
- 2011, No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected[4] - (Full text)
- 2013, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir in a Subset of Patients With Chronic Fatigue Syndrome[5] - (Full text)
- 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study[6] - (Full text)
Articles[edit | edit source]
Talks and interviews[edit | edit source]
- May 2011 - Keynote Speaker at the 6th Invest in ME International ME Conference - Speech Title: Strategies for ME Research and Collaboration[7]
- 2012, ME/CFS Alert Episode 23:
- The Open Medicine Institute, Part 1,
- The Open Medicine Institute, Part 2,
- The Open Medicine Institute, Part 3
- 2012, ME/CFS Alert Episode 22:
- 2012, 7th Invest in ME International ME Conference - Strategies for ME Research and Collaboration[8]
- 2013, 8th Invest in ME International ME Conference Keynote Speaker: Strategies for ME Research and Collaboration[9]
- 2014, YouTube - What Works For Chronic Fatigue Syndrome
- 2014, 9th Invest in ME International ME Conference 2014 - No title of talk given
- 2014, ME/CFS Alert Episode 56: Dr. Andreas Kogelnik on the "Real Thrust" of ME/CFS Research
- 2014, ME/CFS Alert Episode 55: Interview with Dr. Andreas Kogelnik
- 17 Feb 2014, Dr. Andreas Kogelnik and Llewellyn King on Sirius XM Radio POTUS Channel 124
- 23 Jan 2014, “The Jim Bohannon Show” with guests, Dr. Andreas Kogelnik, Ryan Prior and Llewellyn King
References[edit | edit source]
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "The Clinic". Open Medicine Institute. Retrieved April 17, 2019.
- ↑ "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019.
- ↑ Kogelnik, AM; Loomis, K; Hoegh-Petersen, M; Rosso, F; Hischier, C; Montoya, JG. "Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue". Journal of Clinical Virology. 37: Suppl 1:S33-8. doi:10.1016/S1386-6532(06)70009-9. PMID 17276366.
- ↑ Knox, K.; Carrigan, D.; Simmons, G.; Teque, F.; Zhou, Y.; Hackett, J.; Qiu, X.; Luk, K.-C.; Schochetman, G.; Kogelnik, AM (July 1, 2011). "No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected". Science. 333 (6038): 94–97. doi:10.1126/science.1204963. ISSN 0036-8075.
- ↑ Montoya, JG; Kogelnik, AM; Bhangoo, M; Lunn, MR; Flamand, L; Merrihew, LE; Watt, T; Kubo, JT; Paik, J; Desai, M (2013), "Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.", Journal of Medical Virology, 85 (12): 2101-9, doi:10.1002/jmv.23713, PMID 23959519
- ↑ Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
- ↑ "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
- ↑ "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
- ↑ "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
